File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Influence of interleukin-1 gene polymorphism on the outcome of supportive periodontal therapy explored by a multi-factorial periodontal risk assessment model (PRA).

TitleInfluence of interleukin-1 gene polymorphism on the outcome of supportive periodontal therapy explored by a multi-factorial periodontal risk assessment model (PRA).
Authors
Issue Date2003
PublisherQuintessence Publishing Co Ltd. The Journal's web site is located at http://www.quintessencepublishing.co.uk/catalog/product_info.php?cPath=3&products_id=239
Citation
Oral Health Prev Dent, 2003, v. 1 n. 1, p. 17-27 How to Cite?
AbstractBACKGROUND: Multi-factorial risk models have been proposed to enhance the ability to predict risk for the progression of treated chronic periodontitis. AIMS: to study if the outcomes of supportive periodontal therapy (SPT) based on a multi-factorial periodontal risk assessment are influenced by IL-1 gene polymorphism (IP) status. MATERIAL AND METHODS: Information about the IP and smoking status, clinical periodontal conditions and age related bone level measurements were used to calculate a peridontal risk assessment model (PRA). The surface area of this diagram was calculated for 224 subjects who had participated in an SPT program over four years. Baseline and 4-year follow-up data were studied in relation to the IP status. RESULTS: Positive IP tests were obtained for 80/224 (35.7%) of the subjects. At baseline the mean PRA for the IP positive group was 79.9 units, which at year four had increased to 81.3 units (mean diff: 1.4 units, S.D.+/-16.5, p<0.45, 95% CI: 2.3 to 5.1). At baseline and year four the mean PRA for the IP negative group was 44.2 and 38.6 units, respectively. This difference was statistically significant (mean diff: 5.6, S.D.+/-16.1, p<0.001, 95% CI: 3.0 to 8.3). Independent t-tests confirmed that the IP status was significantly associated with a less favorable change in PRA over the four-year period (PRA difference: 7.04, t=3.01, p<0.003, 95% CI: 2.4 to 11.65). Bleeding on probing, and probing depth values alone did not differ between positive and negative IP status. Regression analysis demonstrated that the best-fit model for change in PRA included bleeding on probing at baseline, IP status, proportional alveolar bone loss in relation to the age, and gender. CONCLUSION: The PRA allowed the assessment of the outcomes of SPT therapy. Subjects with positive IP did not respond to individualized SPT as favorably as did IP negative subjects.
Persistent Identifierhttp://hdl.handle.net/10722/154356
ISSN
2015 Impact Factor: 0.69
2015 SCImago Journal Rankings: 0.325

 

DC FieldValueLanguage
dc.contributor.authorPersson, GRen_US
dc.contributor.authorMatuliené, Gen_US
dc.contributor.authorRamseier, CAen_US
dc.contributor.authorPersson, REen_US
dc.contributor.authorTonetti, MSen_US
dc.contributor.authorLang, NPen_US
dc.date.accessioned2012-08-08T08:24:51Z-
dc.date.available2012-08-08T08:24:51Z-
dc.date.issued2003en_US
dc.identifier.citationOral Health Prev Dent, 2003, v. 1 n. 1, p. 17-27en_US
dc.identifier.issn1602-1622en_US
dc.identifier.urihttp://hdl.handle.net/10722/154356-
dc.description.abstractBACKGROUND: Multi-factorial risk models have been proposed to enhance the ability to predict risk for the progression of treated chronic periodontitis. AIMS: to study if the outcomes of supportive periodontal therapy (SPT) based on a multi-factorial periodontal risk assessment are influenced by IL-1 gene polymorphism (IP) status. MATERIAL AND METHODS: Information about the IP and smoking status, clinical periodontal conditions and age related bone level measurements were used to calculate a peridontal risk assessment model (PRA). The surface area of this diagram was calculated for 224 subjects who had participated in an SPT program over four years. Baseline and 4-year follow-up data were studied in relation to the IP status. RESULTS: Positive IP tests were obtained for 80/224 (35.7%) of the subjects. At baseline the mean PRA for the IP positive group was 79.9 units, which at year four had increased to 81.3 units (mean diff: 1.4 units, S.D.+/-16.5, p<0.45, 95% CI: 2.3 to 5.1). At baseline and year four the mean PRA for the IP negative group was 44.2 and 38.6 units, respectively. This difference was statistically significant (mean diff: 5.6, S.D.+/-16.1, p<0.001, 95% CI: 3.0 to 8.3). Independent t-tests confirmed that the IP status was significantly associated with a less favorable change in PRA over the four-year period (PRA difference: 7.04, t=3.01, p<0.003, 95% CI: 2.4 to 11.65). Bleeding on probing, and probing depth values alone did not differ between positive and negative IP status. Regression analysis demonstrated that the best-fit model for change in PRA included bleeding on probing at baseline, IP status, proportional alveolar bone loss in relation to the age, and gender. CONCLUSION: The PRA allowed the assessment of the outcomes of SPT therapy. Subjects with positive IP did not respond to individualized SPT as favorably as did IP negative subjects.en_US
dc.languageengen_US
dc.publisherQuintessence Publishing Co Ltd. The Journal's web site is located at http://www.quintessencepublishing.co.uk/catalog/product_info.php?cPath=3&products_id=239en_US
dc.relation.ispartofOral Health Prev Denten_US
dc.subject.meshAdulten_US
dc.subject.meshAge Factorsen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAlveolar Bone Loss - Classificationen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshDisease Progressionen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshGingival Hemorrhage - Classificationen_US
dc.subject.meshHumansen_US
dc.subject.meshInterleukin-1 - Geneticsen_US
dc.subject.meshLongitudinal Studiesen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPeriodontal Pocket - Classificationen_US
dc.subject.meshPeriodontitis - Etiology - Therapyen_US
dc.subject.meshPolymorphism, Genetic - Geneticsen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshRisk Assessmenten_US
dc.subject.meshSex Factorsen_US
dc.subject.meshSmokingen_US
dc.subject.meshTooth Loss - Classificationen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleInfluence of interleukin-1 gene polymorphism on the outcome of supportive periodontal therapy explored by a multi-factorial periodontal risk assessment model (PRA).en_US
dc.typeArticleen_US
dc.identifier.emailLang, NP:nplang@hkucc.hku.hken_US
dc.identifier.authorityLang, NP=rp00031en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid15643745-
dc.identifier.scopuseid_2-s2.0-2442465357en_US
dc.identifier.volume1en_US
dc.identifier.issue1en_US
dc.identifier.spage17en_US
dc.identifier.epage27en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridPersson, GR=7101853867en_US
dc.identifier.scopusauthoridMatuliené, G=7801433083en_US
dc.identifier.scopusauthoridRamseier, CA=8921696800en_US
dc.identifier.scopusauthoridPersson, RE=35584452800en_US
dc.identifier.scopusauthoridTonetti, MS=35602248900en_US
dc.identifier.scopusauthoridLang, NP=7201577367en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats